DWM
LCTX icon

Destination Wealth Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Destination Wealth Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-500,245
Closed -$655K – 665
2019
Q1 		$655K Sell
500,245
-26,000
-5% -$32.3K 0.04% 109
2018
Q4 		$480K Sell
526,245
-75,253
-13% -$115K 0.03% 111
2018
Q3 		$1.24M Buy
+601,498
New +$1.26M 0.07% 96
2018
Q2 		– Sell
-601,498
Closed -$1.42M – 589
2018
Q1 		$1.42M Hold
601,498
– – 0.09% 88
2017
Q4 		$1.13M Sell
601,498
-74,295
-11% -$162K 0.07% 89
2017
Q3 		$1.68M Hold
675,793
– – 0.11% 84
2017
Q2 		$1.86M Hold
675,793
– – 0.12% 85
2017
Q1 		$2.04M Hold
675,793
– – 0.14% 77
2016
Q4 		$2.13M Hold
675,793
– – 0.16% 74
2016
Q3 		$2.31M Hold
675,793
– – 0.18% 72
2016
Q2 		$1.54M Sell
675,793
-2,172
-0.3% -$5.33K 0.13% 74
2016
Q1 		$2.43M Sell
677,965
-56,949
-8% -$127K 0.23% 58
2015
Q4 		$2.43M Hold
734,914
– – 0.23% 58
2015
Q3 		$1.78M Hold
734,914
– – 0.2% 62
2015
Q2 		$2.15M Buy
+734,914
New +$2.85M 0.14% 99
2015
Q1 		– Sell
-736,772
Closed -$2.22M – 109
2014
Q4 		$2.22M Hold
736,772
– – 0.22% 51
2014
Q3 		$1.87M Hold
736,772
– – 0.2% 54
2014
Q2 		$1.81M Hold
736,772
– – 0.19% 61
2014
Q1 		$1.96M Hold
736,772
– – 0.21% 57
2013
Q4 		$2.14M Hold
736,772
– – 0.22% 57
2013
Q3 		$2.26M Hold
736,772
– – 0.26% 53
2013
Q2 		$2.35M Buy
+736,772
New +$2.36M 0.29% 54

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Destination Wealth Management's LCTX Position: Q2 2019 in Review

Destination Wealth Management sold out of Lineage Cell Therapeutics (LCTX) in Q2 2019, closing a stake of 500,245 shares — an estimated $655K sold.

Destination Wealth Management first reported a position in LCTX in Q2 2013 and held it in 22 quarters. The position peaked at $2.43M in Q1 2016. 107 funds tracked by Wall St. Rank hold LCTX as of Q2 2019.

  • Destination Wealth Management reported no remaining Lineage Cell Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Destination Wealth Management sold 500,245 Lineage Cell Therapeutics shares in Q2 2019, an estimated $655K.
  • Destination Wealth Management first reported a position in Lineage Cell Therapeutics in Q2 2013 and held it in 22 quarters.
  • Destination Wealth Management's Lineage Cell Therapeutics position peaked at $2.43M in Q1 2016.
  • 107 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2019.

Based on Destination Wealth Management's 13F filing for Q2 2019, filed 19 Jul 2019.